Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys' Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees.

GlobeNewsWire • Feb 12, 2026

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026

RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today issued a corporate update highlighting several recent and upcoming clinical and regulatory milestones.

GlobeNewsWire • Jan 6, 2026

Mineralys: Pre-NDA Feedback Sets Stage For A Pivotal 2026

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million. MLYS's lorundrostat demonstrated significant efficacy in lowering systolic blood pressure, with compelling results in both real-world and specialty settings. Regulatory risk is reduced following positive pre-NDA FDA feedback and JAMA recognition, with NDA submission expected late 2025 or early 2026.

Seeking Alpha • Dec 28, 2025

The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar

Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.

Zacks Investment Research • Dec 26, 2025

4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow

MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.

Zacks Investment Research • Dec 24, 2025

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears

New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period.

The Motley Fool • Dec 23, 2025

Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA editors –

GlobeNewsWire • Dec 12, 2025

Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet

The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Dec 5, 2025

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

New York City-based Findell Capital Management added 250,000 shares of MLYS, valued at $9.5 million, in the third quarter. The purchase marked a new position for Findell, which reported holding no shares of MLYS in the previous quarter.

The Motley Fool • Nov 27, 2025

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 146,000 shares of Mineralys common stock to one new non-executive employee.

GlobeNewsWire • Nov 26, 2025